高齢者に対する膀胱留置カテーテル抜去後の排尿管理 : 超音波膀胱内尿量測定の有効性

膀胱留置カテーテル抜去後の高齢者の排尿自立に向けた援助を検討するために、手術目的等で膀胱内留置カテーテルを留置した７名の高齢患者を対象に、カテーテル抜去後に超音波膀胱内尿量測定器「ゆりりん」による残尿測定を行った。留置期間が１～5日の場合、抜去後6時間以内に自然排尿があり、残尿は少なかった。留置期間が9日、23日となった患者では抜去後6時間以内の自然排尿がなく、「ゆりりん」での測定で残尿を認め、導尿を行った。3名の「ゆりりん」による測定値と導尿による尿量を比較した結果、誤差は20ml～70ml、誤差率5％～26％であったことから、超音波膀胱内尿量測定」はカテーテル抜去後の残尿測定において有用であることが示唆された

Analysis of miRNA Expression in Breast Cancer

Triple-negative breast cancer (TNBC), lacking estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor (HER2) expression, is resistant to conventional therapies. Recent studies have focused on microRNAs (miRNAs) as novel molecular targets for treating TNBC because they modulate gene expression and tumor progression. In the current study, we analyzed the expression of selected miRNAs (miR-145 and miR-182) and tumor promoting factors such as Fascin and poly (ADP-ribose) polymerase (PARP) in human TNBC tissues and "Luminal A" breast cancer tissues, which express ER and PgR, but not HER2, as well as breast cancer cell lines including the triple-negative MDA-MB-231 and Luminal A MCF-7. The results showed that miR-145 and miR-182 were expressed in Luminal A breast cancer tissues and MCF-7 cells, but not in TNBC tissues and MDA-MB-231 cells. In contrast, Fascin and PARP proteins were highly expressed in TNBC and MDA-MB-231, but poorly expressed in Luminal A tissues and MCF-7 cells, indicating a negative correlation between expression of these miRNAs and that of the tumor promoting factors Fascin and PARP. The current study therefore suggests that miR-145 and miR-182 could be potential novel therapeutic targets for TNBC therapy